Potassium-sparing diuretics increase fluid loss through urine while reducing the secretion of potassium. They are generally weak diuretics.
| Category | Examples |
|---|---|
| ENaC Blockers | Amiloride and triamterene |
| Mineralocorticoid receptor antagonists (MRAs) | Spironolactone, eplerenone, and finerenone |
- Mechanism of action
- ENaC blockers directly block epithelial sodium channels (ENaC)
- Natriuresis
- Reduced potassium excretion due to loss of electrical gradient
- MRAs block mineralocorticoid receptors in the distal nephron
- Reduced Na+ and water reabsorption
- Potassium and hydrogen retention (potassium-sparing)
- MRAs also block mineralocorticoid receptors in the heart and blood vessels → reduced cardiac remodelling (cardioprotection)
- ENaC blockers directly block epithelial sodium channels (ENaC)
- Indications
- Resistant hypertension
- Heart failure
- Edema
- When 2 diuretics are required or in patients that tend to develop hypokalemia with other diuretics
- Ascites
- Spironolactone is the preferred diuretic in ascites
- Liddle’s syndrome – a congenital metabolic alkalosis
- Conn’s syndrome
- Adverse effects
- Hyperkalemia
- Metabolic acidosis
- MRAs cause gynaecomastia
- This is less common with eplerenone
- Important precautions to observe when prescribing MRAs to patients with CHF
- Carefully monitor K+ levels
- Monitor symptoms of hyperkalemia
- Changes in cognition
- Muscle weakness
- Fatigue
- Keep patient on K+ restricted diet
- Avoid foods that grow in ground such as potatoes and bananas
- Keep patient on loop diuretic
- Discontinue K+ sparing diuretics such as amiloride and triamterine)